CytoChip

What CytoChip does

CytoChip Inc. is a private diagnostic technology company founded in 2015 by Caltech researchers and headquartered in Irvine, California, with a Product Development Center in Suzhou, China. The company has developed the OneChip Platform, which miniaturizes fluorescent flow cytometry into a disposable microfluidic cartridge with built-in reagents and internal quality control, enabling laboratory-grade Complete Blood Count (CBC) testing at the point of care in approximately 8 minutes. Its flagship product, the CitoCBC analyzer, is the first cartridge-based CBC system to receive FDA 510(k) clearance (K240402) and CLIA Waiver (CW240006) in the United States (February 2025) and a CE Mark in Europe (December 2024), delivering a 16-parameter CBC with a 5-part white blood cell differential from a finger-prick or venous sample.

CytoChip operates a razor-and-blade revenue model, selling the CitoCBC desktop analyzer (hardware) alongside recurring disposable cartridges (consumables). A second product, CitoPRP, was introduced in July 2025 for platelet-rich plasma preparation using the same cartridge architecture. Pricing is quote-based and not publicly disclosed. Go-to-market in the U.S. is anchored by an exclusive distribution agreement with Henry Schein (signed January 2026) targeting ambulatory care settings — physician offices, urgent care centers, and critical access hospitals with 25 or fewer beds — augmented by direct e-commerce via the CytoChip Store and industry-conference lead generation (ADLM 2025).

The company has raised approximately $12 million across three to four funding rounds from strategic investors including Fosun Pharma (2017) and Cowin Venture (2016, 2021), with the most recent disclosed round of $8.5 million completed in August 2022. Customer concentration is centered on the Henry Schein channel for U.S. reach and an SMB/decentralized healthcare provider base; no large enterprise customer logos or recurring enterprise contracts are disclosed. The company's competitive position rests on a regulatory first-mover advantage, proprietary Caltech-originated microfluidics IP, and a recurring cartridge revenue stream in a market where over 90% of U.S. physician offices currently lack on-site CBC infrastructure.

Name

CytoChip

Legal name

CytoChip Inc.

Website

https://cytochipinc.com

Company type

Private

Founded year

2015

Operating status

Operating

Headcount range

11–50 employees

Short description

CytoChip Inc. is a private Irvine, California-based diagnostics company whose OneChip Platform miniaturizes fluorescent flow cytometry into disposable cartridges, enabling the first FDA CLIA-Waived cartridge-based Complete Blood Count test (CitoCBC) for point-of-care use in physician offices, urgent care centers, and critical access hospitals.

Ownership category

akta.pro rank

Product category

Point-of-care hematology diagnostics

NAICS

Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), In-Vitro Diagnostic Substance Manufacturing (325413)

SIC

Surgical & Medical Instruments & Apparatus (3841), In Vitro & In Vivo Diagnostic Substances (2835)

akta.pro primary industry

Hematology POCT (CBC/hemoglobin/hematocrit) (HLAHAOAD)

akta.pro secondary industry

Flow Cytometry & Cellular Analysis Diagnostics (HLAHAAAF)

Keywords

• Point-of-care diagnostics
• Cartridge-based hematology
• Microfluidic blood testing
• CLIA waived CBC
• Fluorescent flow cytometry

Headquarters

HQ city

Irvine

HQ country

United States

HQ region

North America

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Supply Chain, Marketing or Sales, Operations

Revenue model

1. CitoCBC Analyzer Sales: Sale of the CitoCBC desktop analyzer device for point-of-care hematology testing
2. Disposable Cartridge Sales: Recurring sales of disposable test cartridges (OneChip) that integrate microfluidics and reagents for single-use testing
3. CitoPRP System (Emerging): Future revenue from CitoPRP system for platelet-rich plasma preparation using disposable cartridges

Pricing tiers

Go-to-market motion2 records

Distribution channels3 records

Marketing channels3 records

Core offering

CytoChip develops and sells point-of-care hematology diagnostic systems built on its proprietary OneChip Platform, which miniaturizes fluorescent flow cytometry into a disposable microfluidic cartridge. Its flagship product, CitoCBC, is the first cartridge-based Complete Blood Count (CBC) system with FDA 510(k) clearance and CLIA Waiver, delivering a 16-parameter CBC with 5-part WBC differential in approximately 8 minutes. The company also sells CitoPRP, a cartridge-based system for platelet-rich plasma preparation.

Product overview

CytoChip is a diagnostic technology company offering point-of-care hematology solutions built on its proprietary OneChip Platform. The core product is CitoCBC, the world's first cartridge-based CBC system with FDA CLIA Waiver, delivering lab-quality 5-part differential CBC results in approximately 8 minutes. The company also offers CitoPRP for platelet-rich plasma preparation. The OneChip Platform technology miniaturizes fluorescent flow cytometry into disposable cartridges, enabling decentralized testing in physician offices, pharmacies, and other non-laboratory settings.

Differentiator

Problem solved

Functional benefit

Brands

• OneChip: Mini portal for diagnostic data platform incorporating fluorescent flow cytometer integrated into disposable microfluidic cartridge

Products and services

• CitoCBC Analyzer and Cartridge System The CitoCBC system is a desktop point-of-care hematology analyzer paired with disposable OneChip cartridges that performs a 16-parameter Complete Blood Count with 5-part WBC differential in approximately 8 minutes. It is the world's first cartridge-based CBC system to receive FDA 510(k) clearance and CLIA Waiver, intended for physician offices, urgent care centers, pharmacies, nursing homes, critical access hospitals, and other non-laboratory settings.
• CitoPRP System CitoPRP is a cartridge-based platelet-rich plasma (PRP) preparation system that accurately measures platelet concentrations up to 4 billion cells/mL using a disposable cartridge, with no manual dilution required and no risk of analyzer clogging. It is offered as an add-on capability to the CytoChip cartridge-based diagnostic platform for clinics and practices performing PRP procedures.
• OneChip Disposable Test Cartridges OneChip disposable test cartridges are the single-use consumable that runs on CytoChip's desktop analyzers. Each cartridge integrates microfluidics, reagents, and built-in internal quality control material, requires minimal sample volume, supports room temperature storage, and is self-contained for safe disposal after a CBC run.

Quantifiable outcome

• Over 90% of U.S. physician offices lack infrastructure for on-site CBC testing, representing a significant addressable market gap
• +3 more outcomes

Named customers3 records

Segments2 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

One partnership is on record.

• Henry Schein, Inc.coreChannel Partner/ Reseller/ Distributor · 6 January 2026Henry Schein entered into an exclusive distribution agreement with CytoChip on January 6, 2026 to distribute the CitoCBC system across ambulatory care settings in the United States. Henry Schein serves as the exclusive distributor for physician offices, urgent care centers, and critical access hospitals with 25 patient beds or fewer. This partnership enables CytoChip to leverage Henry Schein's extensive healthcare provider network and established sales infrastructure.

Scale indicators4 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• PixCell Medical: Developer of the HemoScreen, a cartridge-based, FDA-cleared point-of-care CBC analyzer that competes directly with CytoChip's CitoCBC in physician offices and urgent care settings using a similar disposable-cartridge, CLIA-Waivable workflow.
• Boule Diagnostics: Specialized hematology diagnostics vendor offering small-batch CBC and 5-part differential analyzers used in decentralized and resource-limited settings, overlapping with CytoChip's compact, low-infrastructure positioning.

Broad incumbents

• Sysmex: Global leader in hematology analyzers (XN series) that serves as the reference analyzer against which CitoCBC's performance is validated; competes broadly in CBC testing across hospitals and reference labs.
• Beckman Coulter: Major clinical hematology and IVD platform whose analyzers compete with CytoChip's lab-grade CBC offering; medical advisor Jane Emerson has consulted for Beckman Coulter, evidencing adjacency.
• Abbott (i-STAT and Piccolo): Large diagnostics incumbent with point-of-care chemistry/hematology systems and CLIA-Waivable devices sold through similar physician-office channels; represents a potential competitor if Abbott extends POC CBC.
• Siemens Healthineers: Broad diagnostics and hematology instrument manufacturer with established hospital and reference-lab presence and growing POC offerings relevant to CytoChip's physician-office market.
• HORIBA Medical: Hematology and clinical chemistry instrument manufacturer with established CBC analyzer lines serving small-to-mid hospital and ambulatory labs; competes for the same customer base CytoChip targets via Henry Schein.

Emerging players

• Sight Diagnostics: Emerging point-of-care blood-count and malaria diagnostics company pursuing similar decentralized testing use cases with disposable-cartridge-style hardware; partial overlap with CytoChip's POC CBC focus.
• QBC Diagnostics (Pressure BioSciences): Specializes in point-of-care hematology analyzers using centrifuged buffy-coat methodology, directly competing with CitoCBC in physician-office and field CBC testing.
• HemoSonics: Point-of-care viscoelastic hemostasis testing company using microfluidic cartridge technology; comparable in cartridge-based POC diagnostics architecture though focused on coagulation rather than CBC.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks3 records

Key highlights7 records

Customer concentration

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Funding overview

Funding rounds4 records

Investors3 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about CytoChip